

Iron Deficiency in Adults

A Review

Michael Auerbach, MD; Thomas G. DeLoughery, MD; Jennifer S. Tirnauer, MD

IMPORTANCE Absolute iron deficiency, defined as low iron stores with or without anemia, affects approximately 2 billion people worldwide and 14% of adults in the US. Iron-deficiency anemia, defined as low hemoglobin due to low iron stores, affects approximately 1.2 billion people worldwide, including 10 million in the US.

OBSERVATIONS Absolute iron deficiency progresses from low iron stores to iron-deficiency anemia. Individuals with nonanemic iron deficiency or iron-deficiency anemia may be asymptomatic or experience fatigue, irritability, depression, difficulty concentrating, restless legs syndrome (32%-40%), pica (40%-50%), dyspnea, lightheadedness, exercise intolerance, and worsening heart failure (HF). Symptom prevalences vary depending on age, comorbidities (eg, chronic kidney disease [CKD], HF), and severity and rate of development of iron deficiency. The most common causes of iron deficiency are bleeding (menstrual, gastrointestinal), impaired iron absorption (atrophic gastritis, celiac disease, bariatric surgical procedures), inadequate dietary iron intake, and pregnancy. In high-income countries, approximately 38% of nonpregnant, reproductive-age women have iron deficiency without anemia and about 13% have iron-deficiency anemia. During the third trimester of pregnancy, iron deficiency affects up to 84% of pregnant women, based on data from high-income countries. Additional risk factors include use of nonsteroidal anti-inflammatory drugs, inflammatory bowel disease (IBD [13%-90%]), and other chronic inflammatory conditions, such as CKD (24%-85%), HF (37%-61%), and cancer (18%-82%). Testing for iron deficiency is indicated for patients with anemia and/or symptoms of iron deficiency (fatigue, pica, or restless legs syndrome) and should be considered for those with risk factors such as heavy menstrual bleeding, pregnancy, or IBD. Iron deficiency is diagnosed by low serum ferritin (typically <30 ng/mL) in individuals without inflammatory conditions or by transferrin saturation (iron/total iron binding capacity \times 100) less than 20%. Causes of iron deficiency should be identified and treated. Oral iron (ferrous sulfate 325 mg/d or on alternate days) is typically first-line therapy. Intravenous iron is indicated for patients with oral iron intolerance, poor absorption (celiac disease, post-bariatric surgical procedure), chronic inflammatory conditions (CKD, HF, IBD, cancer), ongoing blood loss, and during the second and third trimesters of pregnancy.

CONCLUSIONS AND RELEVANCE Iron deficiency and iron-deficiency anemia are common conditions that may cause symptoms such as fatigue, exercise intolerance, and difficulty concentrating. Ferritin and/or transferrin saturation are required for diagnosis and screening. Oral iron is first-line therapy for most patients. Intravenous iron is used for individuals who do not tolerate or have impaired absorption of oral iron, those with ongoing blood loss, certain chronic inflammatory conditions (IBD, CKD, HF, cancer), and during the second and third trimesters of pregnancy.

JAMA. 2025;333(20):1813-1823. doi:10.1001/jama.2025.0452
Published online March 30, 2025.

 [Supplemental content](#)

 [CME at \[jamacmelookup.com\]\(https://jamacmelookup.com\)](#)

Author Affiliations: Auerbach Hematology and Oncology, Baltimore, Maryland (Auerbach); Georgetown University School of Medicine, Washington, DC (Auerbach); Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland (DeLoughery); UpToDate, Wolters Kluwer, Waltham, Massachusetts (Tirnauer).

Corresponding Author: Michael Auerbach, MD, Auerbach Hematology and Oncology, Georgetown University School of Medicine, 5233 King Ave, #308, Baltimore, MD 21237 (mauerbachmd@abhemonc.com).

Iron is an important component of hemoglobin and myoglobin and is used in neurotransmitter synthesis and mitochondrial energy generation. Absolute iron deficiency, typically defined as ferritin less than 30 ng/mL or transferrin saturation (TSAT) less than 20% (calculated as iron/total iron binding capacity \times 100), affects nearly 2 billion people worldwide.¹ Based on data from the National Health and Nutrition Examination Survey (NHANES) 2017 to 2020, which included 8021 US adults, approximately 14% (95% CI, 13%-15%) had absolute iron deficiency.² Another study using NHANES data from 2003 to 2020 reported that among 3490 nonpregnant females aged 12 to 21 years, the percentage of iron deficiency was 38.6% (95% CI, 35.8%-40.9%), using a 25-ng/mL ferritin cutoff to diagnose iron deficiency.³ In a study of 644 066 reproductive-age nonpregnant women in Canada, 38.3% had iron deficiency without anemia and 13% had iron-deficiency anemia.⁴

Absolute iron deficiency may be associated with cognitive dysfunction ("brain fog" [decreased concentration/attention]), mood changes (irritability, depression), fatigue, exercise intolerance, worsening heart failure (HF), restless legs syndrome (RLS), and pica (craving nonfood substances, such as ice). If the cause of iron deficiency is not diagnosed and treated, iron-deficiency anemia may develop.⁵

Iron-deficiency anemia, typically defined as ferritin less than 30 ng/mL or TSAT less than 20%, and hemoglobin below the reference range (<12 g/dL in women and <13 g/dL in men), affects more than 1.2 billion people worldwide and approximately 10 million people in the US.^{1,6} Individuals with iron-deficiency anemia may have more severe symptoms than those who have iron deficiency without anemia, especially if anemia develops quickly (days to weeks rather than months). The World Health Organization Global Burden of Disease study lists iron-deficiency anemia as 1 of the top 5 causes of years lived with disability.⁶

This Review focuses on the screening, diagnosis, and treatment of absolute iron deficiency with or without anemia. Functional iron deficiency, identified by normal or elevated ferritin levels with low TSAT (<20%),⁷ which can result in functional iron-deficiency anemia, also known as anemia of chronic disease, anemia of inflammation, or iron-restricted erythropoiesis, is briefly mentioned.

Methods

PubMed was searched for English-language studies of iron deficiency and its treatment in adults published between January 1, 2014, and November 1, 2024. Guidelines not indexed in PubMed were added. We prioritized systematic reviews and randomized clinical trials (RCTs) and reviewed 350 articles. Of these, 86 were included, consisting of 33 RCTs, 20 interventional trials, 16 observational studies, 10 systematic reviews, 6 guideline documents, and 1 review. Study participants in this Review are described as reported in the original research. For characterizations of sex and gender, terms such as *women*, *females*, and *mothers* follow the primary source.

Discussion and Observations

Pathophysiology

Iron is necessary for the production and function of hemoglobin (which binds oxygen) and myoglobin as well as other cellular pro-

cesses, including mitochondrial energy production and neurotransmitter synthesis.⁸ Without treatment, absolute iron deficiency may progress to severe, symptomatic anemia.

Iron is absorbed from the diet. The most efficiently absorbed form is heme iron, derived from red meat, poultry, and seafood. Nonheme iron is available from legumes and vegetables (eg, dried beans, dark leafy greens) and supplemented cereals. Both forms of iron are absorbed by intestinal enterocytes and transported via the iron exporter ferroportin to circulating transferrin in the blood. Transferrin transports iron to the liver and spleen for storage as ferritin, the primary form of stored iron, and hemosiderin in the bone marrow.⁹ Iron is primarily stored in the reticuloendothelial system and salvaged from senescent red blood cells (RBCs) by macrophages. Approximately 1 to 2 mg of iron is lost in sweat and stool daily (Figure 1).

Hepcidin, a hormone synthesized predominantly in the liver, regulates iron absorption and storage. Hepcidin blocks ferroportin and promotes its degradation,¹⁰ thereby preventing iron absorption and the release of stored iron from reticuloendothelial cells of the liver, spleen, and bone marrow. Hepcidin decreases when iron stores are low, increasing iron absorption and the release of stored iron. Conversely, hepcidin increases with recent iron intake, adequate iron stores, and inflammation, suppressing iron absorption and ferritin release from storage. When hepcidin is elevated, stored iron is inaccessible for hemoglobin synthesis,⁶ and prolonged hepcidin elevation can lead to functional iron deficiency and associated anemia.

Epidemiology and Risk Factors


Absolute iron deficiency results from blood loss, inadequate dietary intake, or impaired iron absorption (Box 1). The most common causes of absolute iron deficiency, with or without anemia, in high-income countries are bleeding (menstrual, gastrointestinal [GI]) and pregnancy.¹¹

Most diets in high-resource countries contain iron sufficient to prevent iron deficiency, although vegetarian and vegan diets and food insecurity may reduce iron intake below the level needed to maintain iron stores, especially in individuals who are menstruating or pregnant.¹² The recommended daily intake of iron for women is 18 mg/d, of which approximately 10% (1.8 mg/d), is absorbed; the average intake in the US is approximately 13 mg/d for women.¹³ Menstruation increases iron requirements to about 2 mg/d.

Pregnancy increases iron requirements by 1000 to 1100 mg.¹⁴ Iron deficiency is common among pregnant individuals. A retrospective study reported absolute iron deficiency (ferritin <30 ng/mL) in 53% of 26 469 pregnant individuals.¹⁵ In 629 primiparous individuals from Ireland who had iron parameters measured longitudinally at 15, 20, and 33 weeks, iron deficiency (ferritin <30 ng/mL or soluble transferrin receptor >4.4 mg/L) was documented in 21%, 44%, and 84% of participants, respectively.¹⁶

Potential GI sources of blood loss include inflammatory bowel disease (IBD), colorectal or gastric cancer, duodenal or gastric ulcers, esophagitis, gastritis, and colonic vascular ectasia. A study of 1036 individuals with IBD reported 27% had iron deficiency and 14% had iron-deficiency anemia.¹⁷ In 2000 outpatients with IBD, 43% had absolute iron deficiency and 12% had iron-deficiency anemia; in these patients, iron deficiency was more common in those with active IBD (71%) vs quiescent disease (24%).¹⁸

Figure 1. Iron Absorption, Storage, and Conservation in the Body



Aspirin or other nonsteroidal anti-inflammatory drugs can cause iron deficiency due to GI blood loss (occult or overt).¹⁹ Chronic proton pump inhibitor (PPI) use reduces iron absorption by increasing gastric pH (low pH is necessary for iron absorption). In a meta-

analysis that included 14 case-control and cohort studies (76 089 patients taking a PPI), the relative risk of iron deficiency among people taking a PPI compared with controls not taking a PPI was 2.56 ($P < .001$).²⁰

Box 1. Causes of Iron Deficiency**Increased Blood Loss**

- Menstruation
- Pregnancy and delivery
- Gastrointestinal cancer
- Gastritis
- Ulcers, including Cameron ulcers (linear ulcers associated with hiatal hernia)
- Inflammatory bowel disease
- Chronic use of aspirin or nonsteroidal anti-inflammatory drugs
- Regular blood donation
- Intense athletic activity
- Hereditary hemorrhagic telangiectasia or other cause of nasal or gastrointestinal arteriovenous malformation
- Hookworm or other parasites
- Meckel diverticulum
- Gross hematuria

Reduced Absorption

- *Helicobacter pylori* infection
- Autoimmune or atrophic gastritis
- Inflammatory bowel disease
- Bariatric surgical procedure
- Long-term use of a proton pump inhibitor
- Celiac disease
- Rare hereditary conditions, such as atransferrinemia and iron refractory iron-deficiency anemia

Chronic Inflammation

- Cancer
- Rheumatologic disease (rheumatoid arthritis, systemic lupus erythematosus)
- Inflammatory bowel disease
- Chronic kidney disease
- Heart failure
- Endocrine disease (hypothyroidism)

In some low-resource countries, intestinal parasites (*Strongyloides* species, other soil-transmitted helminths, and *Schistosoma* species) cause absolute iron deficiency due to GI blood loss. Depending on their geographic origin, 8% to 86% of refugees to North America have parasitic infections that may cause iron deficiency.²¹

Iron deficiency may also result from decreased absorption of dietary iron due to intestinal conditions, such as atrophic gastritis, celiac disease, or a bariatric surgical procedure. In a meta-analysis of high-quality observational studies and RCTs comparing individuals infected with *Helicobacter pylori* (which causes achlorhydria, ulcers, and gastritis) with uninfected people, infection was associated with a higher rate of iron-deficiency anemia (odds ratio [OR], 1.72 [95% CI, 1.23-2.42]; 14 studies) and iron deficiency without anemia (pooled OR, 1.33 [95% CI, 1.15-1.54]; 30 studies).²²

Celiac disease can cause occult blood loss from intestinal inflammation, decreased iron absorption through intestinal villus atrophy, and inflammation-induced hepcidin upregulation.^{23,24} In a study including 382 adults with celiac disease, 145 (46%) had iron-deficiency anemia.²⁵ A systematic review that included 2998 patients with iron-deficiency anemia reported 3.2% had celiac disease.²⁶

Iron deficiency is common in chronic diseases, such as chronic kidney disease (CKD [24%-85%]), IBD (13%-90%), HF (37%-61%), and cancer (18%-82%).⁵ Obesity is associated with decreased iron absorption because adipose tissue produces hepcidin and induces inflammation, which further stimulates hepcidin production.²⁷ Three studies of 582 patients referred for a bariatric surgical procedure reported absolute iron deficiency with or without anemia in 6% to 22% of patients vs 6% to 7% of patients in the general population.²⁸

Bariatric surgical procedures (Roux-en-Y, biliopancreatic diversions) may further impair iron absorption by bypassing small intestinal absorptive surfaces.²⁹ In 58 premenopausal women who underwent sleeve gastrectomy (n = 26) or Roux-en-Y gastric bypass (n = 32), heme iron (meat-based) absorption (measured by ⁵⁹Fe absorption) decreased from 24% preprocedure to 6% postprocedure and nonheme (plant-based) iron absorption decreased from 11% preprocedure to 5% postprocedure.³⁰

Even in the absence of known risk factors, iron deficiency is highly prevalent. In the cross-sectional 2017 to 2020 NHANES study of 8021 US adults, 11% (95% CI, 10%-11%) without anemia, HF, CKD, or current pregnancy had absolute iron deficiency.²

Signs and Symptoms of Absolute Iron Deficiency

Individuals with absolute iron deficiency with or without anemia can be asymptomatic or may have 1 or more of the following signs or symptoms: fatigue; decreased exercise tolerance; RLS; pica, including pagophagia (ice craving); depression; and decreased attention and concentration (brain fog). Symptoms are often more severe in individuals with iron-deficiency anemia compared with those who have iron deficiency without anemia.³¹⁻³⁴

Pica, especially pagophagia, is common (up to 50%) in individuals with absolute iron deficiency.³³ In 987 consecutive patients with absolute iron deficiency and iron-deficiency anemia (mean hemoglobin, 10.4 g/dL), 40% had pagophagia, 40% had RLS, and 22% had both.³³

Physical signs of iron deficiency may include tongue depapillation, cheilosis, koilonychia (spoon nails), and diffuse nonscarring scalp alopecia. With more severe deficiency, including iron-deficiency anemia, patients may have pallor, pale conjunctiva, and, with severe anemia, tachycardia or a cardiac flow murmur.

RLS, which causes unpleasant sensations, cramps, and a sensation of needing to move the legs,³⁵ is associated with decreased brain iron (measured by magnetic resonance imaging) and with absolute iron deficiency with or without anemia. Two studies (1248 individuals with absolute iron deficiency with or without anemia) reported RLS in 32% and 40% of participants, respectively.^{33,36} Two studies that included 335 patients with RLS reported absolute iron deficiency in 25% and 42% of patients, respectively.^{37,38} In a meta-analysis of 10 RCTs (455 patients with RLS with or without anemia), both oral iron (2 trials) and intravenous (IV) iron (8 trials) supplementation significantly reduced leg discomfort and sleep disturbance symptoms relative to placebo (International Restless Legs Syndrome [IRLS] score decreased by 3.55 points).³⁹

Iron Deficiency in Pregnancy

Iron deficiency may be associated with adverse fetal, neonatal, and maternal outcomes. In a study from Sweden of 532 232 pregnancies, adjusted for socioeconomic status, genetic background, and

pregnancy complications, children of mothers with anemia diagnosed prior to 30 weeks' gestation, compared with children of mothers without anemia prior to 30 weeks' gestation, had increased rates of autism spectrum disorders (4.9% vs 3.5%; OR, 1.44 [95% CI, 1.13-1.84]), attention deficit hyperactivity disorder (9.3% vs 7.1%; OR, 1.37 [95% CI, 1.14-1.64]), and intellectual disability (3.1% vs 1.1%; OR, 2.20 [95% CI, 1.61-3.01]).⁴⁰ In a study of 18 948 443 pregnancies in China, postpartum hemorrhage (PPH) occurred in 2.07% of participants with prepartum anemia vs 0.81% of participants without anemia; the risk of PPH correlated with the severity of anemia (adjusted odds ratio [aOR] for mild anemia, 1.45 [95% CI, 1.43-1.47]; aOR for moderate anemia, 3.53 [95% CI, 3.47-3.60]; aOR for severe anemia, 15.65 [95% CI, 15.10-16.22]).⁴¹ In a study involving 515 270 pregnant individuals from Canada, 65 906 of whom had anemia, prepartum anemia was associated with increased need for blood transfusions (5.1 per 1000 among women without anemia; aOR for mild anemia, 2.45 [95% CI, 1.74-3.45]; aOR for moderate anemia, 21.3 [95% CI, 12.2-37.3]), longer hospital stays, and higher rates of pre-eclampsia, placenta previa, and cesarean delivery.⁴² In 166 566 deliveries in the US, in univariable analysis, antenatal anemia was significantly associated with maternal death (0.04% vs 0.01%; $P < .001$), transfusion during labor (2.9% vs 1%; $P < .001$), postpartum transfusion (6.7% vs 3.7%; $P < .001$), and PPH (13.8% vs 6.9%; $P < .001$). With multivariable logistic regression, anemia remained independently associated with severe maternal morbidity (a composite of maternal death, eclampsia, thrombosis, transfusion, hysterectomy, and intensive care unit admission), with an aOR of 2.44 (95% CI, 1.86-2.23).⁴³ Although iron deficiency accounts for 75% of all anemias during pregnancy, the cause of anemia was not always identified in the above studies, and associations between iron-deficiency anemia and adverse pregnancy outcomes may not reflect causation.

Diagnosis

Testing for Iron Deficiency

All patients with symptoms of iron deficiency or with anemia (hemoglobin below the reference limit) or unexplained microcytosis (mean corpuscular volume [MCV] <80 fL) should undergo testing with ferritin and/or TSAT (Figure 2), along with complete blood cell count if not done previously.

Serum ferritin is the first-line initial test for iron deficiency because iron deficiency is the only cause of low ferritin.^{44,45} Based on expert consensus, the ferritin level to define absolute iron deficiency is typically less than 30 ng/mL,^{1,46} which has 98% specificity and 92% sensitivity for absent bone marrow iron stores,⁴⁷ the standard for absolute iron deficiency. The sensitivity of ferritin for diagnosing iron deficiency is reduced in inflammatory conditions (IBD, HF, CKD, cancer) because ferritin, which is an acute phase reactant, increases with inflammation. In patients with absolute iron deficiency and a concurrent inflammatory condition, ferritin levels rarely exceed 100 ng/mL.⁴⁴ International and professional society guidelines vary in ferritin cutoffs for different conditions and populations (IBD, CKD, RLS, individuals who are menstruating, adults 65 years or older); therefore, if concern for iron deficiency exists despite ferritin of greater than 50 ng/mL, TSAT should be measured.¹¹

TSAT quantifies the percentage of transferrin that is saturated with iron, and low TSAT (<16%-20%) indicates lack of bioavailable, circulating iron. Low TSAT is helpful to diagnose iron deficiency in individuals with IBD, CKD, cancer, and HF, in whom serum ferritin levels may be elevated due to inflammation.^{48,49} TSAT should not be tested within 5 to 9 hours of ingesting iron-containing foods, vitamins, or supplements because serum iron increases with recent iron ingestion; fasting is not required if these ingestions are avoided.

Reticulocytosis (reticulocyte count >100 000/microL) following iron therapy is considered diagnostic of iron deficiency because it demonstrates that previously low levels of iron limited RBC production. Absence of reticulocytosis within approximately 1 week after iron therapy suggests alternate or concomitant diagnoses other than iron deficiency. Bone marrow aspiration with iron staining is rarely required to diagnose iron deficiency.

Hemoglobin and MCV are poor surrogates for iron deficiency and inadequate for diagnosis because anemia and microcytosis are late-stage findings. In a study that included 345 pregnant individuals who had complete blood cell count and ferritin level data, hemoglobin less than 11 g/dL and MCV less than 80 fL each only had a sensitivity of 30% for diagnosing iron deficiency (ferritin <30 ng/mL) during the first trimester.⁵⁰ Of 1749 individuals diagnosed with iron deficiency during any trimester of pregnancy, 50.5% did not have anemia or microcytosis.⁵⁰

Screening


Recommendations for routine screening of asymptomatic, nonanemic, at-risk individuals for iron deficiency vary by professional organization. The American Society of Hematology, which has not previously issued screening recommendations for iron deficiency, is currently developing a guideline on this topic. The European Hematology Association (EHA) recommends screening patients at risk for developing iron deficiency, including athletes; vegetarians; regular blood donors; individuals who are menstruating; adults older than 65 years; people with certain chronic diseases (HF, CKD) or impaired absorption (celiac disease, short bowel syndrome, post-bariatric surgical procedure); individuals with bleeding disorders (von Willebrand disease, hemophilia); patients taking anticoagulants, anti-inflammatory or antiplatelet drugs, or PPIs; those with chronic or parasitic infections (hookworm); and socioeconomically disadvantaged individuals.¹¹

For pregnant individuals, guidelines on screening for iron deficiency vary. The 2024 US Preventive Services Task Force guideline found insufficient evidence to recommend for or against screening pregnant individuals for iron deficiency in the absence of anemia.⁵¹ The American College of Obstetricians and Gynecologists recommends screening pregnant individuals for anemia and testing for iron deficiency only if anemia is present.⁵² In contrast, the International Federation of Gynecology and Obstetrics and the EHA recommend screening all pregnant individuals and reproductive-age females for iron deficiency.^{11,53}

Etiology of Iron Deficiency

The etiology of iron deficiency should be assessed in all patients (Figure 2). Heavy menstrual bleeding may be determined by the frequency of changing sanitary pads and/or tampons (>3/hour or during nighttime) and passage of clots (>1 in).⁵⁴ If menstrual bleeding is heavy, testing is indicated for anatomic lesions, such as uterine

Figure 2. Evaluation and Treatment of Iron Deficiency



fibroids or polyps (ultrasound, hysteroscopy), and for bleeding disorders, such as von Willebrand disease.¹¹

Inadequate dietary iron intake or malabsorption due to autoimmune gastritis or celiac disease can typically be identified by history and laboratory testing. Iron-poor diet, PPI use, or a bariatric surgical procedure can be determined from the history. For persons with iron deficiency and upper GI symptoms (dyspepsia, nausea, anorexia, epigastric pain), the American Gastroenterological Association (AGA) practice guidelines⁴⁵ recommend testing for *H pylori* and celiac disease.⁵⁵

Patients with an uncertain cause of absolute iron deficiency after initial evaluation should typically undergo esophagogastroduodenoscopy and colonoscopy, even if asymptomatic.⁴⁵ An AGA technical review evaluating 18 studies (12 040 asymptomatic men and postmenopausal women with iron-deficiency anemia) reported that upper endoscopy detected upper GI cancer (gastric and esopha-

geal) in 2.0% of patients and colonoscopy detected lower GI cancer in 8.9% of patients.⁵⁶ These rates were approximately 100-fold higher than those seen with general population screening. For patients with unrevealing initial endoscopies and no other causes of blood loss, capsule endoscopy can be considered, although supporting evidence is lacking.

Treatment

Oral iron is first-line treatment for most individuals with absolute iron deficiency (Figure 2). Oral iron preparations are widely available, inexpensive, and effective in treating absolute iron deficiency in most individuals when taken appropriately. A typical dose (ferrous sulfate, 325 mg) contains 60 mg of elemental iron and is taken once every other day or once daily. Treatment with oral iron should continue

until ferritin, TSAT, and hemoglobin (in those with iron-deficiency anemia) return to the normal range. Use of enteric-coated and timed-release oral iron preparations reduces iron absorption, which may extend duration of therapy to 2 or more years.⁵⁷

For patients with RLS who have a ferritin level less than 75 ng/mL and TSAT less than 45%, a 2018 guideline from the International Restless Legs Syndrome Study Group (IRLSSG) recommends daily use of oral ferrous sulfate with vitamin C for 12 weeks.⁵⁸

Many individuals taking oral iron report nausea, constipation, diarrhea, metallic taste, and/or greenish-black stool.⁵⁹ A meta-analysis that included 20 RCTs with 3168 participants comparing ferrous sulfate with placebo showed that adverse effects were more common with oral iron than placebo (OR, 2.32; $P < .001$).⁵⁹ This meta-analysis also reported that adverse GI effects were more common with oral ferrous sulfate (doses ranging from 100 to 400 mg daily) than IV iron (OR, 3.05; $P < .001$), based on 23 RCTs with 3663 participants. In patients with IBD, oral iron reduced gut bacterial diversity.⁶⁰⁻⁶³

Alternate-day administration of equal doses of oral iron improves tolerance with similar efficacy. A masked, placebo-controlled RCT of 150 premenopausal women with absolute iron deficiency (ferritin ≤ 30 ng/mL) reported similar efficacy with oral iron taken daily for 90 days (serum ferritin, 43.8 ng/mL) and every other day for 180 days (serum ferritin, 44.8 ng/mL; $P = .98$), with significantly fewer GI adverse effects (nausea, stomach pain) in the alternate-day group (longitudinal prevalence ratio for GI adverse effects on days of iron intake, 1.56 [95% CI, 1.38-1.77]; $P < .001$).⁶⁴

Increased dietary iron intake alone is insufficient to replete iron stores in patients with absolute iron deficiency (Box 2).^{65,66} Fiber, calcium, coffee, and tea decrease oral iron absorption, so avoiding them within 1 hour before and after taking oral iron improves iron absorption. Iron absorption increases when oral iron is taken with vitamin C or meat protein.^{12,67,68}

Monitoring and Follow-Up After Oral Iron

Adherence to oral iron therapy, adverse effects, and resolution of symptoms should be monitored because many individuals discontinue iron due to GI symptoms. Severity of iron deficiency informs the frequency of monitoring. Checking hemoglobin every 3 months during the first year after a diagnosis of iron deficiency and twice yearly during years 2 to 3 has been recommended by the EHA.¹¹ For iron-deficiency anemia, a minimum increase in hemoglobin of 1 g/dL is expected 2 weeks after starting oral iron.⁶⁹

For oral iron intolerance, options include decreasing the dose and/or frequency, substituting a different formulation, or switching to IV iron (Figure 2).⁶⁹ If there is no increase in ferritin and/or TSAT and no increase in hemoglobin despite adherence to oral iron, evaluation is indicated for conditions such as autoimmune gastritis or celiac disease that impair iron absorption, and for ongoing GI blood loss or other causes of anemia.

IV Iron

Oral iron may not be adequate for treating iron deficiency or iron-deficiency anemia in individuals with heavy menstrual or chronic GI bleeding or those with impaired absorption. In these circumstances, IV iron should be first-line treatment (Figure 2). The eTable in the Supplement lists relevant clinical trials in these populations.

Box 2. Frequently Asked Questions About Iron Deficiency

Who should be tested for iron deficiency?

Testing for iron deficiency with a serum ferritin and/or transferrin saturation is appropriate for anyone with symptoms of iron deficiency (eg, fatigue, pica, restless legs syndrome), anemia, microcytosis, or risk factors such as ongoing blood loss from heavy menstrual bleeding, heart failure, chronic kidney disease, inflammatory bowel disease, cancer, or a bariatric surgical procedure. Guidelines vary about whether asymptomatic pregnant individuals should be screened for iron deficiency.

Which foods are high in iron, and can iron deficiency be treated by diet alone?

Adequate dietary iron is important for preventing iron deficiency, but after iron deficiency develops, the typical iron deficit of 1000 mg, plus daily needs of 1 to 5 mg, cannot be provided by diet alone. Foods highest in iron include animal meats, fortified cereals, and legumes (eg, lentils, chickpeas, beans [lima, soy, kidney, and white beans]).

How should oral iron be taken?

Oral iron can be taken once daily or every other day; compared with daily use, iron ingestion every other day has a similar efficacy and fewer adverse effects. Vitamin C may increase iron absorption, and calcium-containing foods, tea, and coffee consumed within 1 hour before and after taking oral iron may decrease iron absorption.

IV iron dosing, frequency, and duration depend on the cause of iron deficiency (Box 1). In the second and third trimesters of pregnancy, IV iron ensures sufficient iron delivery to the fetus for development.⁷⁰ Data suggest IV iron corrects anemia and fatigue faster than oral iron. In a randomized trial of 196 patients with postpartum iron-deficiency anemia, the median hemoglobin 6 weeks after therapy was 12.3 g/dL (95% CI, 10.6-13.8) with IV iron vs 11.7 g/dL (95% CI, 9.9-12.6) with oral iron.⁷¹

IV iron is first-line treatment for individuals with iron deficiency after a bariatric surgical procedure because these patients cannot adequately absorb oral iron.⁷²⁻⁷⁴ For patients with IBD, IV iron causes fewer GI adverse effects than oral iron.⁶⁰⁻⁶³ In inflammatory conditions, such as rheumatoid arthritis, CKD, IBD, cancer, and HF, oral iron may not be adequately absorbed, and IV iron may be necessary (Figure 1).^{1,69,75,76}

IV iron is recommended by the 2018 IRLSSG guideline for patients with moderate to severe RLS who have a ferritin level less than 100 ng/mL and TSAT less than 45% who have a contraindication to oral iron, did not improve or did not tolerate oral iron, have a condition affecting oral iron absorption, or need a more rapid response than would be achieved with oral iron.⁵⁸

There are no absolute contraindications to IV iron. However, IV iron is not recommended in the first trimester of pregnancy due to lack of safety data.

Comparison of IV Iron Formulations

In the US, 6 IV iron formulations are available: low molecular weight iron dextran, ferric gluconate, iron sucrose, ferumoxytol, ferric carboxymaltose (FCM), and ferric derisomaltose (FDI). Multiple studies have shown no difference in efficacy among these formulations. Low molecular weight iron dextran, ferumoxytol, FCM, and FDI can be administered in a single infusion over 15 to 60 minutes

Table. Intravenous (IV) Iron Formulations

Agent	Low-molecular-weight iron dextran (INFeD [US]; CosmoFer [Europe])	Ferumoxytol (Feraheme)	Ferric carboxymaltose (Injectafer [US]; Ferinject [Europe])	Ferric derisomaltose (Monoferric [US]; Monofer [Europe])
Approved dosing	100 mg	510 mg	750 mg (US) 1000 mg (Europe)	1000 mg (20 mg/kg if <66 kg)
Optimal dosing	1000 mg over 60 min	1020 mg over 30 min	750 mg × 2 (US) 1000 mg (Europe) Both over 15 min	1000 mg over 20 min
Adverse events and special considerations ^a	Should not be confused with high molecular weight iron dextran no longer marketed	Inform radiologist if magnetic resonance imaging is performed within 8 wk of administration Exercise caution if substituting the generic formulation due to concerns about adverse events	May cause hypophosphatemia Avoid if serum phosphorus is low and monitor serum phosphorus in individuals receiving more than 1 infusion	Formerly known as iron isomaltoside

Refer to the eTable in the [Supplement](#) for representative clinical trials using these formulations.

(frequency, 1%-4%). Anaphylaxis is possible with any medication, including IV iron, but true anaphylaxis with IV iron is exceedingly rare (<0.0005%).

^a All formulations can cause infusion reactions that are not histamine mediated

(Table).^{77,78} Iron sucrose and ferric gluconate require multiple IV infusions over several weeks.

Adverse Effects of IV Iron

IV iron does not typically cause GI adverse effects.⁷⁹ In a double-masked, double-dummy RCT of 96 patients with RLS, IV ferumoxytol and oral iron were similarly effective, decreasing IRLSS scores by 7.9 points with IV iron and 10.1 points with oral iron ($P = .27$).⁸⁰ The patients treated with IV ferumoxytol had fewer adverse events (55% with oral ferrous sulfate [mostly GI] vs 11% with ferumoxytol [mostly minor infusion reactions]).⁸⁰

Use of IV FCM is associated with increased risk of hypophosphatemia, which can be prolonged and associated with symptoms of fatigue, cramps, and muscle weakness.⁸¹ A randomized trial of 97 patients with IBD and iron-deficiency anemia reported hypophosphatemia in 8.3% of patients receiving FDI vs 51% of patients receiving FCM (adjusted risk difference, -42.8% [95% CI, -57.1% to -24.6%]; $P < .001$).⁸² If more than 1 FCM infusion is given, serum phosphorous should be tested (on day 7, prior to the second infusion) and if hypophosphatemia is present, the second dose should be held.

Anaphylaxis occurs in approximately 1 of every 200 000 IV iron infusions, with no significant differences among formulations. A meta-analysis of 103 RCTs comparing IV iron ($n = 10\,390$) with oral iron ($n = 4044$), placebo ($n = 3335$), and no iron ($n = 1329$) reported no increase in serious adverse events and no anaphylaxis with IV iron.⁷⁹

Minor infusion reactions consisting of facial flushing, chest pressure, and back tightness can occur with IV iron; these reactions are not associated with wheezing, stridor, periorbital edema, or hemodynamic compromise. In 35 737 infusions ($n = 12\,237$ patients), minor infusion reactions occurred in 1.4% to 4.3% of patients.⁸³ Premedication with diphenhydramine was associated with increased minor infusion reactions (38.6% with vs 1.7% without diphenhydramine).⁸³

Infusion reactions are believed to be complement-mediated and resolve with stopping the infusion. This phenomenon has been called CARPA (complement activation-related pseudoallergy) or the

Fishbane reaction.^{84,85} Upon resolution, the infusion can be restarted at a slower rate, as CARPA reactions rarely recur. Infusion reactions should not be treated with epinephrine and diphenhydramine because these treatments are not effective and may be associated with adverse events, such as tachycardia and somnolence.

Monitoring After IV Iron

Hemoglobin, ferritin, and TSAT should be checked 4 weeks after IV iron infusion, and if they indicate insufficient repletion (ferritin <30 ng/mL; TSAT <20%), additional IV iron should be administered. Additional follow-up depends on the etiology of iron deficiency.

Transfusion

RBC transfusion should be reserved for patients requiring an immediate increase in hemoglobin, such as those with severe anemia (hemoglobin <7 g/dL) and life-threatening bleeding, cardiac ischemia, or hemodynamic instability due to anemia.⁸⁶ Although RBC transfusion treats anemia, it does not supply iron for erythropoiesis and does not adequately replete iron stores.

Limitations

This review has several limitations. First, it is not a systematic review, and the quality of included literature was not formally evaluated. Second, some relevant studies may have been missed. Third, some topics, such as functional iron deficiency, were not discussed.

Conclusions

Iron deficiency and iron-deficiency anemia are common conditions that may cause symptoms such as fatigue, exercise intolerance, and difficulty concentrating. Ferritin and/or TSAT are required for diagnosis and screening. The etiology of iron deficiency should be sought and treated. Oral iron is first-line therapy for most patients. IV iron is used for individuals who do not tolerate or have impaired absorption of oral iron, those with ongoing blood loss, certain chronic inflammatory conditions (IBD, CKD, HF, cancer), and during the second and third trimesters of pregnancy.

ARTICLE INFORMATION

Accepted for Publication: January 13, 2025.

Published Online: March 30, 2025.
doi:10.1001/jama.2025.0452

Conflict of Interest Disclosures: Dr Auerbach reported receiving research funding from Covis Pharma for data management; personal fees from Pharmacosmos for educational, nonpromotional programs; and being an author for UpToDate outside the submitted work. Dr DeLoughery reported being an author for UpToDate regarding iron deficiency. No other disclosures were reported.

Submissions: We encourage authors to submit papers for consideration as a Review. Please contact Kristin Walter, MD, at kristin.walter@jamanetwork.org.

REFERENCES

- Camaschella C. Iron deficiency. *Blood*. 2019;133(1):30-39. doi:10.1182/blood-2018-05-815944
- Tawfik YMK, Billingsley H, Bhatt AS, et al. Absolute and functional iron deficiency in the US, 2017-2020. *JAMA Netw Open*. 2024;7(9):e2433126. doi:10.1001/jamanetworkopen.2024.33126
- Weyand AC, Chaitoff A, Freed GL, Sholzberg M, Choi SW, McGann PT. Prevalence of iron deficiency and iron-deficiency anemia in US females aged 12-21 years, 2003-2020. *JAMA*. 2023;329(24):2191-2193. doi:10.1001/jama.2023.8020
- Wen S, Nisenbaum R, Weyand AC, Tang GH, Auerbach M, Sholzberg M. High prevalence of iron deficiency and socioeconomic disparities in laboratory screening of non-pregnant females of reproductive age: a retrospective cohort study. *Am J Hematol*. 2024;99(8):1492-1499. doi:10.1002/ajh.27352
- Abuisha M, Itani H, El Masri R, Antoun J. Prevalence of iron deficiency (ID) without anemia in the general population presenting to primary care clinics: a cross-sectional study. *Postgrad Med*. 2020;132(3):282-287. doi:10.1080/00325481.2020.1715701
- Miller JL. Iron deficiency anemia: a common and curable disease. *Cold Spring Harb Perspect Med*. 2013;3(7):a011866. doi:10.1101/cshperspect.a011866
- Kowdley KV, Gochanour EM, Sundaram V, Shah RA, Handa P. Hepcidin signaling in health and disease: ironing out the details. *Hepatol Commun*. 2021;5(5):723-735. doi:10.1002/hep4.1717
- Dutt S, Hamza I, Bartnikas TB. Molecular mechanisms of iron and heme metabolism. *Annu Rev Nutr*. 2022;42:311-335. doi:10.1146/annurev-nutr-062320-112625
- Vogt AS, Arsiwala T, Mohsen M, Vogel M, Manolova V, Bachmann MF. On iron metabolism and its regulation. *Int J Mol Sci*. 2021;22(9):4591. doi:10.3390/ijms22094591
- Evstatiev R, Gasche C. Iron sensing and signalling. *Gut*. 2012;61(6):933-952. doi:10.1136/gut.2010.214312
- Iolascon A, Andolfo I, Russo R, et al; EHA-SWG Red Cell and Iron. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. *Hemasphere*. 2024;8(7):e108. doi:10.1002/hem3.108
- Hurrell R, Egli I. Iron bioavailability and dietary reference values. *Am J Clin Nutr*. 2010;91(5):1461S-1467S. doi:10.3945/ajcn.2010.28674F
- Martens K, DeLoughery TG. Sex, lies, and iron deficiency: a call to change ferritin reference ranges. *Hematology Am Soc Hematol Educ Program*. 2023;2023(1):617-621. doi:10.1182/hematology.2023000494
- Bothwell TH. Iron requirements in pregnancy and strategies to meet them. *Am J Clin Nutr*. 2000;72(1)(suppl):257S-264S. doi:10.1093/ajcn/72.1.257S
- Teichman J, Nisenbaum R, Lausman A, Sholzberg M. Suboptimal iron deficiency screening in pregnancy and the impact of socioeconomic status in a high-resource setting. *Blood Adv*. 2021;5(22):4666-4673. doi:10.1182/bloodadvances.2021004352
- McCarthy EKS, Schneck D, Basu S, et al. Longitudinal evaluation of iron status during pregnancy: a prospective cohort study in a high-resource setting. *Am J Clin Nutr*. 2024;120(5):1259-1268. doi:10.1016/j.ajcnut.2024.08.010
- Peyrin-Biroulet L, Bouguen G, Laharie D, et al; CARENFER study group. Iron deficiency in patients with inflammatory bowel diseases: a prospective multicenter cross-sectional study. *Dig Dis Sci*. 2022;67(12):5637-5646. doi:10.1007/s10620-022-07474-z
- Loveikyte R, Boer M, van der Meulen CN, et al; Dutch Initiative on Crohn and Colitis (ICC). Anemia and iron deficiency in outpatients with inflammatory bowel disease: ubiquitous yet suboptimally managed. *J Clin Med*. 2022;11(22):6843. doi:10.3390/jcm11226843
- McQuilten ZK, Thao LTP, Pasricha SR, et al. Effect of low-dose aspirin versus placebo on incidence of anemia in the elderly: a secondary analysis of the Aspirin in Reducing Events in the Elderly trial. *Ann Intern Med*. 2023;176(7):913-921. doi:10.7326/M23-0675
- Ali MD. Proton pump inhibitors' use and risk of iron deficiency anaemia: a systematic review and meta-analysis. *Curr Rev Clin Exp Pharmacol*. 2023;18(2):158-166. doi:10.2174/2772432817666220307121220
- US Centers for Disease Control and Prevention. Intestinal parasites. May 15, 2024. Accessed January 28, 2025. <https://www.cdc.gov/immigrant-refugee-health/hcp/domestic-guidance/intestinal-parasites.html>
- Hudak L, Jaraissy A, Haj S, Muhsen K. An updated systematic review and meta-analysis on the association between *Helicobacter pylori* infection and iron deficiency anemia. *Helicobacter*. 2017;22(1). doi:10.1111/hel.12330
- Fasano A, Catassi C. Celiac disease. *N Engl J Med*. 2012;367(25):2419-2426. doi:10.1056/NEJMcp1113994
- Hershko C, Patz J. Ironing out the mechanism of anemia in celiac disease. *Haematologica*. 2008;93(12):1761-1765. doi:10.3324/haematol.2008.000828
- Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. *Blood*. 2007;109(2):412-421. doi:10.1182/blood-2006-07-031104
- Mahadev S, Laszkowska M, Sundström J, et al. Prevalence of celiac disease in patients with iron deficiency anemia—a systematic review with meta-analysis. *Gastroenterology*. 2018;155(2):374-382.e1. doi:10.1053/j.gastro.2018.04.016
- Alshwaiyat NM, Ahmad A, Wan Hassan WMR, Al-Jamal HAN. Association between obesity and iron deficiency (review). *Exp Ther Med*. 2021;22(5):1268. doi:10.3892/etm.2021.10703
- Björklund G, Peana M, Pivina L, et al. Iron deficiency in obesity and after bariatric surgery. *Biomolecules*. 2021;11(5):613. doi:10.3390/biom11050613
- Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. *Am J Hematol*. 2008;83(5):403-409. doi:10.1002/ajh.21106
- Ruz M, Carrasco F, Rojas P, et al. Heme- and nonheme-iron absorption and iron status 12 mo after sleeve gastrectomy and Roux-en-Y gastric bypass in morbidly obese women. *Am J Clin Nutr*. 2012;96(4):810-817. doi:10.3945/ajcn.112.039255
- Wassef A, Nguyen QD, St-André M. Anaemia and depletion of iron stores as risk factors for postpartum depression: a literature review. *J Psychosom Obstet Gynaecol*. 2019;40(1):19-28. doi:10.1080/0167482X.2018.1427725
- Fernandez-Jimenez MC, Moreno G, Wright I, Shih PC, Vaguero MP, Remacha AF. Iron deficiency in menstruating adult women: much more than anemia. *Womens Health Rep (New Rochelle)*. 2020;1(1):26-35. doi:10.1089/whr.2019.0011
- Achebe MO, Mandell E, Jolley K, et al. Pagophagia and restless legs syndrome are highly associated with iron deficiency and should be included in histories evaluating anemia. *Am J Hematol*. 2023;98(1):E8-E10. doi:10.1002/ajh.26775
- Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER, a randomized, placebo-controlled study. *PLoS One*. 2014;9(4):e94217. doi:10.1371/journal.pone.0094217
- Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J; participants of the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. *Sleep Med*. 2003;4(2):101-119. doi:10.1016/S1389-9457(03)00010-8
- Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. *Am J Hematol*. 2013;88(4):261-264. doi:10.1002/ajh.23397
- Aul EA, Davis BJ, Rodnitzky RL. The importance of formal serum iron studies in the assessment of restless legs syndrome. *Neurology*. 1998;51(3):912. doi:10.1212/WNL.51.3.912
- Zhu XY, Wu TT, Wang HM, et al. Correlates of nonanemic iron deficiency in restless legs syndrome. *Front Neurol*. 2020;11:298. doi:10.3389/fneur.2020.00298

39. Avni T, Reich S, Lev N, Gafter-Gvili A. Iron supplementation for restless legs syndrome—a systematic review and meta-analysis. *Eur J Intern Med*. 2019;63:34–41. doi:10.1016/j.ejim.2019.02.009
40. Wiegersma AM, Dalman C, Lee BK, Karlsson H, Gardner RM. Association of prenatal maternal anemia with neurodevelopmental disorders. *JAMA Psychiatry*. 2019;76(12):1294–1304. doi:10.1001/jamapsychiatry.2019.2309
41. Shi H, Chen L, Wang Y, et al. Severity of anemia during pregnancy and adverse maternal and fetal outcomes. *JAMA Netw Open*. 2022;5(2):e2147046. doi:10.1001/jamanetworkopen.2021.47046
42. Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal and perinatal morbidity and mortality associated with anemia in pregnancy. *Obstet Gynecol*. 2019;134(6):1234–1244. doi:10.1097/AOG.0000000000003557
43. Harrison RK, Lauhon SR, Colvin ZA, McIntosh JJ. Maternal anemia and severe maternal morbidity in a US cohort. *Am J Obstet Gynecol MFM*. 2021;3(5):100395. doi:10.1016/j.ajogmf.2021.100395
44. Guyatt GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of iron-deficiency anemia: an overview. *J Gen Intern Med*. 1992;7(2):145–153. doi:10.1007/BF02598003
45. Ko CW, Siddique SM, Patel A, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia. *Gastroenterology*. 2020;159(3):1085–1094. doi:10.1053/j.gastro.2020.06.046
46. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. *Lancet*. 2021;397(10270):233–248. doi:10.1016/S0140-6736(20)32594-0
47. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. *Clin Chem*. 1998;44(1):45–51. doi:10.1093/clinchem/44.1.45
48. Rohr M, Brandenburg V, Brunner-La Rocca HP. How to diagnose iron deficiency in chronic disease: a review of current methods and potential marker for the outcome. *Eur J Med Res*. 2023;28(1):15. doi:10.1186/s40001-022-00922-6
49. Grote Beverborg N, Klip IT, Meijers WC, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. *Circ Heart Fail*. 2018;11(2):e004519. doi:10.1161/CIRCHEARTFAILURE.117.004519
50. Chao HX, Zack T, Leavitt AD. Screening characteristics of hemoglobin and mean corpuscular volume for detection of iron deficiency in pregnancy. *Obstet Gynecol*. 2025;145(1):91–94. doi:10.1097/AOG.0000000000000573
51. US Preventive Services Task Force. Screening and supplementation for iron deficiency and iron deficiency anemia during pregnancy: US Preventive Services Task Force recommendation statement. *JAMA*. 2024;332(11):906–913. doi:10.1001/jama.2024.15196
52. ACOG. Anemia in pregnancy: ACOG practice bulletin, number 233. *Obstet Gynecol*. 2021;138(2):e55–e64. doi:10.1097/AOG.0000000000004477
53. FIGO. Iron deficiency and anaemia in women and girls. September 12, 2023. Accessed February 4, 2024. <https://www.figo.org/resources/figo-statements/iron-deficiency-and-anaemia-women-and-girls>
54. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. *Am J Obstet Gynecol*. 2004;190(5):1216–1223. doi:10.1016/j.ajog.2003.11.015
55. Kulnigg-Dabsch S, Resch M, Oberhuber G, Klinglmueller F, Gasche A, Gasche C. Iron deficiency workup reveals high incidence of autoimmune gastritis with parietal cell antibody as reliable screening test. *Semin Hematol*. 2018;55(4):256–261. doi:10.1053/j.seminhematol.2018.07.003
56. Rockey DC, Altayar O, Falck-Ytter Y, Kalmaz D. AGA technical review on gastrointestinal evaluation of iron deficiency anemia. *Gastroenterology*. 2020;159(3):1097–1119. doi:10.1053/j.gastro.2020.06.045
57. Thankachan P, Bose B, Subramanian R, Koneri R, Kurpad AV. Fractional iron absorption from enteric-coated ferrous sulphate tablet. *Indian J Med Res*. 2020;151(4):371–374. doi:10.4103/ijmr.IJMR_1464_18
58. Allen RP, Picchietti DL, Auerbach M, et al; International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. *Sleep Med*. 2018;41:27–44. doi:10.1016/j.sleep.2017.11.1126
59. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. *PLoS One*. 2015;10(2):e0117383. doi:10.1371/journal.pone.0117383
60. Malesza JJ, Bartkowiak-Wieczorek J, Winkler-Galicki J, et al. The dark side of iron: the relationship between iron, inflammation and gut microbiota in selected diseases associated with iron deficiency anaemia—a narrative review. *Nutrients*. 2022;14(17):3478. doi:10.3390/nu14173478
61. Loveikyte R, Bourgonje AR, van Goor H, Dijkstra G, van der Meulen-de Jong AE. The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: a review on the conundrum. *Redox Biol*. 2023;68:102950. doi:10.1016/j.redox.2023.102950
62. Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. *Gut*. 2017;66(5):863–871. doi:10.1136/gutjnl-2015-309940
63. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. *Gut*. 2004;53(8):1190–1197. doi:10.1136/gut.2003.035758
64. von Siebenthal HK, Gessler S, Vellelian F, et al. Alternate day versus consecutive day oral iron supplementation in iron-depleted women: a randomized double-blind placebo-controlled study. *EClinicalMedicine*. 2023;65:102286. doi:10.1016/j.eclinm.2023.102286
65. NIH. Iron: fact sheet for health professionals. Updated October 9, 2024. Accessed February 6, 2025. <https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/>
66. Piskin E, Cianciosi D, Gulec S, Tomas M, Capanoglu E. Iron absorption: factors, limitations, and improvement methods. *ACS Omega*. 2022;7(24):20441–20456. doi:10.1021/acsomega.2c01833
67. von Siebenthal HK, Moretti D, Zimmermann MB, Stoffel NU. Effect of dietary factors and time of day on iron absorption from oral iron supplements in iron deficient women. *Am J Hematol*. 2023;98(9):1356–1363. doi:10.1002/ajh.26987
68. Cook JD, Monsen ER. Food iron absorption in human subjects III: comparison of the effect of animal proteins on nonheme iron absorption. *Am J Clin Nutr*. 1976;29(8):859–867. doi:10.1093/ajcn/29.8.859
69. Okam MM, Koch TA, Tran MH. Iron supplementation, response in iron-deficiency anemia: analysis of five trials. *Am J Med*. 2017;130(8):991 e1–991 e8. doi:10.1016/j.amjmed.2017.03.045
70. Awomolo AM, McWhirter A, Sadler LC, Coppola LM, Hill MG. Neonatal outcomes from a randomized controlled trial of maternal treatment of iron deficiency anemia with intravenous ferumoxytol vs oral ferrous sulfate. *Am J Obstet Gynecol MFM*. 2023;5(9):101063. doi:10.1016/j.ajogmf.2023.101063
71. Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. *Vox Sang*. 2017;112(3):219–228. doi:10.1111/vox.12477
72. Auerbach M, Spivak J. Treatment of iron deficiency in the elderly: a new paradigm. *Clin Geriatr Med*. 2019;35(3):307–317. doi:10.1016/j.cger.2019.03.003
73. Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):57–66. doi:10.1182/asheducation-2016.1.57
74. DeLoughery TG, Jackson CS, Ko CW, Rockey DC. AGA clinical practice update on management of iron deficiency anemia: expert review. *Clin Gastroenterol Hepatol*. 2024;22(8):1575–1583. doi:10.1016/j.cgh.2024.03.046
75. Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and anemia: a tight relationship. *Front Physiol*. 2019;10:1294. doi:10.3389/fphys.2019.01294
76. Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. *Acta Haematol*. 2019;142(1):44–50. doi:10.1159/000496492
77. Schaefer B, Tobiasch M, Wagner S, et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. *Bone*. 2022;154:116202. doi:10.1016/j.bone.2021.116202
78. Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. *Eur J Pharm Biopharm*. 2011;78(3):480–491. doi:10.1016/j.ejpb.2011.03.016
79. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. *Mayo Clin Proc*. 2015;90(1):12–23. doi:10.1016/j.mayocp.2014.10.007
80. Short V, Allen R, Earley CJ, et al. A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs

syndrome in patients with iron deficiency anemia. *Am J Hematol*. 2024;99(6):1077-1083. doi:10.1002/ajh.27290

81. Martens KL, Wolf M. Incidence, mechanism, and consequences of IV iron-induced hypophosphatemia. *Hematology Am Soc Hematol Educ Program*. 2023;2023(1):636-639. doi:10.1182/hematology.2023000521

82. Zoller H, Wolf M, Blumenstein I, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel

disease (PHOSPARE-IBD): a randomised clinical trial. *Gut*. 2023;72(4):644-653. doi:10.1136/gutjnl-2022-327897

83. Arastu AH, Elstrott BK, Martens KL, et al. Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions. *JAMA Netw Open*. 2022;5(3):e224488. doi:10.1001/jamanetworkopen.2022.4488

84. Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.

Br J Pharmacol. 2015;172(21):5025-5036. doi:10.1111/bph.13268

85. Macdougall IC, Vernon K. Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. *Am J Nephrol*. 2017;45(1):60-62. doi:10.1159/000451069

86. Carson JL, Stanworth SJ, Dennis JA, et al. Transfusion thresholds for guiding red blood cell transfusion. *Cochrane Database Syst Rev*. 2021;12(12):CD002042. doi:10.1002/14651858.CD002042.pub5

Supplemental Online Content

Auerbach M, DeLoughery TG, Tirnauer JS. Iron deficiency in adults: a review. *JAMA*. Published online March 31, 2025. doi:10.1001/jama.2025.0452

eTable. Representative Clinical Trials Using Iron Formulations

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable. Representative Clinical Trials Using Iron Formulations

Agent	Representative Clinical Trials
Low Molecular Weight Iron Dextran (INFeD [US]; Cosmofer [Europe])	Cancer ¹ Chronic kidney disease ²⁻⁵ Inflammatory bowel disease ⁶ Pediatrics ⁷ Post-partum ⁸ Pregnancy ⁹⁻¹¹ Restless legs syndrome ^{12,13}
Ferumoxytol (Feraheme)	Chronic kidney disease/dialysis ^{14,15} Iron deficiency ¹⁶⁻¹⁹ Pregnancy ²⁰ Restless legs syndrome ²¹
Ferric Carboxymaltose (Injectafer [US]; Ferinject [Europe])	Bariatric surgery ²² Cancer ²³ Cardiac surgery ²⁴ Chronic kidney disease ²⁵⁻²⁷ COPD ²⁸ Fatigue ²⁹ GI bleeding ³⁰ GI disorders ³¹ Heart failure ³² Inflammatory bowel disease ³³⁻³⁵ Iron-deficiency anemia ³⁶⁻³⁸ Menorrhagia ³⁹⁻⁴¹ Pediatrics ⁴² Post-operative anemia ⁴³ Post-partum anemia ⁴⁴⁻⁴⁶ Pregnancy ⁴⁷⁻⁵⁰ Pulmonary hypertension ⁵¹ Restless legs syndrome ⁵²⁻⁵⁴ Runners ⁵⁵ Surgery ⁵⁶
Ferric Derisomaltose (Monoferric [US]; Monofer [Europe])	Cancer ^{57,58} Cardiac surgery ⁵⁹ Chronic kidney disease ^{60,61} Heart failure ⁶² Hip fracture ⁶² Inflammatory bowel disease ⁶³⁻⁶⁵ Iron-deficiency anemia ^{18,66,67} Menorrhagia ⁶⁸ Post-partum hemorrhage ^{69,70} Pregnancy ⁷¹ Surgery ⁷²⁻⁷⁴ Valvular cardiac disease ⁷⁵

1. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. *J Clin Oncol*. Apr 1 2004;22(7):1301-7. doi:10.1200/JCO.2004.08.119
2. Sloan JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. *Am J Kidney Dis*. Apr 2004;43(4):663-70. doi:10.1053/j.ajkd.2003.11.021
3. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. *Am J Kidney Dis*. Jan 1998;31(1):81-6. doi:10.1053/ajkd.1998.v31.pm9428456
4. Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. *Ren Fail*. May 2002;24(3):307-13. doi:10.1081/jdi-120005364
5. Anirban G, Kohli HS, Jha V, Gupta KL, Sakhuja V. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. *Ren Fail*. 2008;30(6):629-38. doi:10.1080/08860220802134631
6. Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis EA. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. *Dig Dis Sci*. Aug 2010;55(8):2327-31. doi:10.1007/s10620-009-1022-y
7. Plummer ES, Crary SE, McCavit TL, Buchanan GR. Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. *Pediatr Blood Cancer*. Nov 2013;60(11):1747-52. doi:10.1002/pbc.24676
8. Daniilidis A, Giannoulis C, Pantelis A, Tantanasis T, Dinas K. Total infusion of low molecular weight iron-dextran for treating postpartum anemia. *Clin Exp Obstet Gynecol*. 2011;38(2):159-61.
9. Tariq N, Ayub R, Khan WU, Ijaz S, Alam AY. Parenteral iron therapy in the treatment of iron deficiency anemia during pregnancy: a randomized controlled trial. *J Coll Physicians Surg Pak*. Mar 2015;25(3):193-7.
10. Lewkowitz AK, Stout MJ, Cooke E, et al. Intravenous versus Oral Iron for Iron-Deficiency Anemia in Pregnancy (IVIDA): A Randomized Controlled Trial. *Am J Perinatol*. Jun 2022;39(8):808-815. doi:10.1055/s-0041-1740003
11. Ayub R, Tariq N, Adil MM, Iqbal M, Junaid A, Jaferry T. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. *J Coll Physicians Surg Pak*. Jul 2008;18(7):424-7.
12. Mehmood T, Auerbach M, Earley CJ, Allen RP. Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease). *Sleep Med*. Dec 2014;15(12):1473-6. doi:10.1016/j.sleep.2014.08.012
13. Cho YW, Allen RP, Earley CJ. Lower molecular weight intravenous iron dextran for restless legs syndrome. *Sleep Med*. Mar 2013;14(3):274-7. doi:10.1016/j.sleep.2012.11.001
14. Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. *Clin J Am Soc Nephrol*. Apr 2014;9(4):705-12. doi:10.2215/CJN.05320513

15. Macdougall IC, Dahl NV, Bernard K, Li Z, Batycky A, Strauss WE. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. *BMC Nephrol.* Apr 3 2017;18(1):117. doi:10.1186/s12882-017-0523-8
16. Vadhan-Raj S, Ford DC, Dahl NV, et al. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study. *Am J Hematol.* Feb 2016;91(2):E3-5. doi:10.1002/ajh.24240
17. Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. *Am J Hematol.* Jun 2014;89(6):646-50. doi:10.1002/ajh.23712
18. Cohen J, Khudanyan A, Lu J, et al. A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency. *Am J Hematol.* Dec 2020;95(12):1572-1577. doi:10.1002/ajh.25995
19. Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. *Am J Hematol.* May 2018;93(5):683-690. doi:10.1002/ajh.25060
20. Awomolo AM, McWhirter A, Sadler LC, Coppola LM, Hill MG. Intravenous infusions of ferumoxytol compared to oral ferrous sulfate for the treatment of anemia in pregnancy: a randomized controlled trial. *Am J Obstet Gynecol MFM.* Sep 2023;5(9):101064. doi:10.1016/j.ajogmf.2023.101064
21. Short V, Allen R, Earley CJ, et al. A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia. *Am J Hematol.* Jun 2024;99(6):1077-1083. doi:10.1002/ajh.27290
22. Schijns W, Boerboom A, de Bruyn Kops M, et al. A randomized controlled trial comparing oral and intravenous iron supplementation after Roux-en-Y gastric bypass surgery. *Clin Nutr.* Dec 2020;39(12):3779-3785. doi:10.1016/j.clnu.2020.04.010
23. Hedenus M, Karlsson T, Ludwig H, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. *Med Oncol.* Dec 2014;31(12):302. doi:10.1007/s12032-014-0302-3
24. Houry M, Tohme J, Sleilaty G, et al. Effects of ferric carboxymaltose on hemoglobin level after cardiac surgery: A randomized controlled trial. *Anaesth Crit Care Pain Med.* Feb 2023;42(1):101171. doi:10.1016/j.accpm.2022.101171
25. Toblli JE, Di Gennaro F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. *PLoS One.* 2015;10(4):e0125528. doi:10.1371/journal.pone.0125528
26. Roger SD, Gaillard CA, Bock AH, et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. *Nephrol Dial Transplant.* Sep 1 2017;32(9):1530-1539. doi:10.1093/ndt/gfw264

27. Macdougall IC, Bock AH, Carrera F, et al. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. *BMC Nephrol.* Jan 17 2017;18(1):24. doi:10.1186/s12882-017-0444-6
28. Santer P, McGahey A, Frise MC, et al. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial. *BMJ Open Respir Res.* Jun 2020;7(1)doi:10.1136/bmjresp-2020-000577
29. Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. *PLoS One.* 2014;9(4):e94217. doi:10.1371/journal.pone.0094217
30. Ferrer-Barcelo L, Sanchis Artero L, Sempere Garcia-Arguelles J, et al. Randomised clinical trial: intravenous vs oral iron for the treatment of anaemia after acute gastrointestinal bleeding. *Aliment Pharmacol Ther.* Aug 2019;50(3):258-268. doi:10.1111/apt.15327
31. Lichtenstein GR, Onken JE. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron. *Dig Dis Sci.* Nov 2018;63(11):3009-3019. doi:10.1007/s10620-018-5204-3
32. Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. *Lancet.* Dec 17 2022;400(10369):2199-2209. doi:10.1016/S0140-6736(22)02083-9
33. Laso-Morales MJ, Vives R, Bisbe E, et al. Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: a randomised controlled trial. *Blood Transfus.* Jul 2022;20(4):310-318. doi:10.2450/2021.0157-21
34. Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol.* Mar 2013;11(3):269-77. doi:10.1016/j.cgh.2012.10.013
35. Bevers N, Van de Vijver E, Aliu A, et al. Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial. *J Pediatr.* May 2023;256:113-119 e4. doi:10.1016/j.jpeds.2022.12.016
36. Pasricha SR, Gilbertson M, Indran T, et al. Safety of rapid injection of undiluted ferric carboxymaltose to patients with iron-deficiency anaemia: a Phase II single-arm study. *Intern Med J.* Aug 2021;51(8):1304-1311. doi:10.1111/imj.15195
37. Keller P, von Kanel R, Hincapie CA, et al. The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. *Sci Rep.* Aug 26 2020;10(1):14219. doi:10.1038/s41598-020-71048-0
38. Drexler C, Macher S, Lindenau I, et al. High-dose intravenous versus oral iron in blood donors with iron deficiency: The IronWoMan randomized, controlled clinical trial. *Clin Nutr.* Mar 2020;39(3):737-745. doi:10.1016/j.clnu.2019.03.025
39. Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. *Int J Gynaecol Obstet.* Apr 2016;133(1):43-8. doi:10.1016/j.ijgo.2015.09.007

40. Lee S, Ryu KJ, Lee ES, Lee KH, Lee JJ, Kim T. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study. *J Obstet Gynaecol Res.* Apr 2019;45(4):858-864. doi:10.1111/jog.13893
41. Ikuta K, Hanashi H, Hirai K, et al. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. *Int J Hematol.* Jan 2019;109(1):41-49. doi:10.1007/s12185-018-2501-8
42. Korczowski B, Farrell C, Falone M, Blackman N, Rodgers T. Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia. *Pediatr Res.* Oct 2023;94(4):1547-1554. doi:10.1038/s41390-023-02644-9
43. Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. *Lancet Haematol.* Sep 2016;3(9):e415-25. doi:10.1016/S2352-3026(16)30078-3
44. Vanobberghen F, Lweno O, Kuemmerle A, et al. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial. *Lancet Glob Health.* Feb 2021;9(2):e189-e198. doi:10.1016/S2214-109X(20)30448-4
45. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. *Obstet Gynecol.* Aug 2007;110(2 Pt 1):267-78. doi:10.1097/01.AOG.0000275286.03283.18
46. Mishra V, Roy P, Gandhi K, Choudhary S, Aggarwal R, Sokabaj S. Safety and Efficacy of Intravenous Ferric Carboxy Maltose in Iron Deficiency Anaemia During Post-partum Period. *J Nepal Health Res Counc.* Jan 1 2018;15(3):208-211. doi:10.3126/jnhrc.v15i3.18841
47. Pasricha SR, Mwangi MN, Moya E, et al. Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial. *Lancet.* May 13 2023;401(10388):1595-1609. doi:10.1016/S0140-6736(23)00278-7
48. Khalafallah AA, Hyppa A, Chuang A, et al. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy. *Semin Hematol.* Oct 2018;55(4):223-234. doi:10.1053/j.seminhematol.2018.04.006
49. Kant S, Haldar P, Malhotra S, Kaur R, Rath R, Jacob OM. Intravenous ferric carboxymaltose rapidly increases haemoglobin and serum ferritin among pregnant females with moderate-to-severe anaemia: A single-arm, open-label trial. *Natl Med J India.* Nov-Dec 2020;33(6):324-328. doi:10.4103/0970-258X.321145
50. Jose A, Mahey R, Sharma JB, et al. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial. *BMC Pregnancy Childbirth.* Feb 4 2019;19(1):54. doi:10.1186/s12884-019-2200-3
51. Howard L, He J, Watson GMJ, et al. Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. *Ann Am Thorac Soc.* Jun 2021;18(6):981-988. doi:10.1513/AnnalsATS.202009-1131OC

52. Cho YW, Allen RP, Earley CJ. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome. *Sleep Med.* Feb 2018;42:7-12. doi:10.1016/j.sleep.2017.11.1134
53. Bae H, Cho YW, Kim KT, Li X, Earley CJ. Ferric carboxymaltose effects on restless legs syndrome and on brain iron in patients with iron deficiency anemia. *Sleep Med.* Sep 2023;109:128-131. doi:10.1016/j.sleep.2023.06.023
54. Bae H, Cho YW, Kim KT, Allen RP, Earley CJ. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. *Sleep Med.* Aug 2021;84:179-186. doi:10.1016/j.sleep.2021.05.036
55. Woods A, Garvican-Lewis LA, Saunders PU, et al. Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners. *PLoS One.* 2014;9(9):e108042. doi:10.1371/journal.pone.0108042
56. Richards T, Baikady RR, Clevenger B, et al. Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. *Lancet.* Oct 24 2020;396(10259):1353-1361. doi:10.1016/S0140-6736(20)31539-7
57. Ng O, Keeler B, Simpson JA, Madhusudan S, Brookes M, Acheson A. Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma. *Nutr Cancer.* Oct 2018;70(7):1106-1117. doi:10.1080/01635581.2018.1504090
58. Birgegard G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. *Pharmacotherapy.* Apr 2016;36(4):402-14. doi:10.1002/phar.1729
59. Ambrosy AP, von Haehling S, Kalra PR, et al. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. *Am J Cardiol.* Aug 1 2021;152:138-145. doi:10.1016/j.amjcard.2021.04.042
60. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. *Nephrol Dial Transplant.* Jan 1 2021;36(1):111-120. doi:10.1093/ndt/gfaa011
61. Bhandari S, Allgar V, Lamplugh A, Macdougall I, Kalra PA. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. *BMC Nephrol.* Mar 30 2021;22(1):115. doi:10.1186/s12882-021-02308-y
62. Lasocki S, Capdevila X, Vielle B, et al. Ferric derisomaltose and tranexamic acid, combined or alone, for reducing blood transfusion in patients with hip fracture (the HiFIT trial): a multicentre, 2 x 2 factorial, randomised, double-blind, controlled trial. *Lancet Haematol.* Sep 2023;10(9):e747-e755. doi:10.1016/S2352-3026(23)00163-1
63. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). *Am J Gastroenterol.* Dec 2013;108(12):1877-88. doi:10.1038/ajg.2013.335

64. Dahlerup JF, Jacobsen BA, van der Woude J, Bark LA, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. *Scand J Gastroenterol*. Nov 2016;51(11):1332-8. doi:10.1080/00365521.2016.1196496
65. Zoller H, Wolf M, Blumenstein I, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. *Gut*. Apr 2023;72(4):644-653. doi:10.1136/gutjnl-2022-327897
66. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. *Am J Hematol*. Sep 2019;94(9):1007-1014. doi:10.1002/ajh.25564
67. Wolf M, Auerbach M, Kalra PA, Glaspy J, Thomsen LL, Bhandari S. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. *Am J Hematol*. Jan 2021;96(1):E11-E15. doi:10.1002/ajh.26015
68. Kawabata H, Tamura T, Tamai S, Fujibayashi A, Sugimura M, Study G. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study. *Int J Hematol*. Nov 2022;116(5):647-658. doi:10.1007/s12185-022-03401-0
69. Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. *J Matern Fetal Neonatal Med*. Sep 2019;32(17):2797-2804. doi:10.1080/14767058.2018.1449205
70. Sugimura M, Ohtani Y, Tamai S, Kishimoto U, Ito N. Ferric derisomaltose for the treatment of iron deficiency anemia with postpartum hemorrhage: Results of a single-arm, open-label, phase 3 study in Japan. *J Obstet Gynaecol Res*. Mar 2023;49(3):946-955. doi:10.1111/jog.15546
71. Hansen R, Sommer VM, Pinborg A, et al. Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial. *Arch Gynecol Obstet*. Oct 2023;308(4):1165-1173. doi:10.1007/s00404-022-06768-x
72. Fung PLP, Lau VNM, Ng FF, Leung WW, Mak TWC, Lee A. Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: A pilot randomised controlled trial. *PLoS One*. 2022;17(6):e0270640. doi:10.1371/journal.pone.0270640
73. Lee B, Kim EJ, Song J, Jung YS, Koo BN. A randomised trial evaluating the effect of intraoperative iron administration. *Sci Rep*. Sep 28 2020;10(1):15853. doi:10.1038/s41598-020-72827-5
74. Yoo S, Bae J, Ro DH, et al. Efficacy of intra-operative administration of iron isomaltoside for preventing postoperative anaemia after total knee arthroplasty: A randomised controlled trial. *Eur J Anaesthesiol*. Apr 1 2021;38(4):358-365. doi:10.1097/EJA.0000000000001389
75. Brautaset Englund KV, Ostby CM, Broch K, et al. Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo. *Clin Transplant*. Jul 2022;36(7):e14695. doi:10.1111/ctr.14695